In plain language
PE-22-28 is an experimental peptide derived from spadin, studied in animals for possible antidepressant and neuroprotective effects. There are no published human trials, so its effects and safety in people are unknown.
What it is explored for
PE-22-28 is an intriguing spadin-derived peptide explored for fast-acting mood and neuroprotective effects through the TREK-1 channel, an unusual and interesting target. The honest picture is that all of this is preclinical, from animal and cell studies, with no human trials yet. Here is where the research interest is currently focused.
- Mood and antidepressant research
- TREK-1 channel studies
- Neuroprotection research
- Synaptic plasticity and neurogenesis research
These are areas of active interest and reported use, not proven outcomes. This peptide carries a preliminary evidence rating, see the evidence summary below for how strong the science actually is.
How it works
PE-22-28 is a shortened analog of spadin, a peptide that blocks a specific potassium channel. Its proposed mechanism comes from animal and cell research.
- TREK-1 channel blockade. Reported to inhibit the TREK-1 potassium channel, a target linked to mood regulation in animal studies.
- Antidepressant-like effects. Associated with reduced depression-like behavior in rodent models, sometimes with a faster onset than standard drugs.
- Synaptic plasticity. Reported to support neurogenesis and synaptic plasticity in preclinical models.
These mechanisms are described only in animal and cell studies. None have been tested in humans.
Evidence summary
The evidence for PE-22-28 is entirely preclinical. A small number of rodent studies report rapid antidepressant-like effects through TREK-1 blockade. There are no published human trials, so it is unknown whether these effects occur in people.
Reported safety & side effects
There is no human safety data for PE-22-28. All available information comes from animal studies. Long-term effects, interactions, and risks in people are unknown.
Frequently asked
Is there human evidence for PE-22-28?
No. All published research is in animals or cell models. There are no controlled human trials, so its effects and safety in people are not established.
What is PE-22-28 studied for?
It is studied mainly as a possible fast-acting antidepressant in rodent models, acting through the TREK-1 potassium channel. These findings have not been confirmed in humans.